The short-acting, non-accumulating profile of CJC-1295 (No DAC), combined with Ipamorelins receptor-specific activity, allows for controlled and targeted stimulation of growth hormone release
The REVEAL-1 study explores whether duodenal mucosal resurfacing, a minimally invasive endoscopic procedure, could help patients maintain their weight loss after they stop taking GLP-1s
If you take it within the window, resume your original weekly day on the next cycle
The STEP UP programme examined weight loss results among participants who took the 2.4 mg per week dose and those who took the 7.2 mg per week dose over a 72-week period
doi: 10.1186/s10194-021-01302-x Noguchi T, Katoh H, Nomura S, Okada K, Watanabe M